Efficacy Analyses Sample Clauses

Efficacy Analyses. Efficacy analyses will be performed on the Efficacy Analysis Set. The primary endpoint, the incidence rate of laboratory confirmed influenza using RT-PCR on nasal swab samples, will be compared between vaccine groups using ▇▇▇▇▇▇’▇ Exact Test. Secondary efficacy endpoints assessing the incidence and severity of influenza-like symptoms will be performed by comparing the incidence of ILI (using the regulatory definition of ILI defined as feeling feverish or having a fever (temperature ≥37.8 C) and at least one of the following symptoms: a cough, and/or sore throat) by ▇▇▇▇▇▇’▇ test exact and symptom severity as an area-under-the- curve (AUC) using a ▇▇▇▇-▇▇▇▇▇▇▇ U Test.
View SourceView Similar (2)
Efficacy Analyses. Similar to those methods described for the primary endpoint in Section 14.5, MMRM will be used for the analysis of the following variables: changes from baseline in MADRS total score, HAM-A total score, , and select individual item and subscale scores. For each model, the comparison of interest will be between SAGE-217 capsule and placebo at the 15-day time point. Model-based point estimates (ie, LS means), 95% confidence intervals, and p-values will be reported. Generalized estimating equation (GEE) methods will be used for the analysis of the following binary variables: HAM-D response (define as ≥50% reduction from baseline in HAM-D total score), HAM-D remission (defined as ≤7.0 HAM-D total score), and CGI-I response. Generalized estimating equation models will include terms for center, treatment, baseline score, assessment time point, and time point-by-treatment as explanatory variables. The comparison of interest will be the difference between SAGE-217 Capsules and placebo at the 15-day time point. Model-based point estimates (ie, odds ratios), 95% confidence intervals, and p-values will be reported. For the CGI-I response analysis, baseline CGI-S score will be included in the model. Descriptive statistics for all scores, change from baseline values, and response variables will be presented by treatment and assessment time point. Summaries will include n, mean, SD, median, minimum, and maximum.
View Source
Efficacy Analyses. No efficacy endpoints are included as part of this study, therefore there is no analysis of efficacy.
View Source
Efficacy Analyses. Unless stated otherwise, all efficacy analyses will compare post-treatment assessment values to the subject’s corresponding baseline assessment value.
View Source
Efficacy Analyses. Statistical analysis of efficacy endpoints will be for descriptive purposes only. Nominal p-values will be based on statistical tests will be 2-sided hypothesis tests performed at the 10% level of significance for main effects. All confidence intervals will be 2-sided 90% confidence intervals, unless stated otherwise. When summarizing diary data by visit, including weekly response endpoints, only the data from the 7 days prior to the subject’s clinic visit will be included.
View Source
Efficacy Analyses. ‌‌‌‌‌ This study defines one primary endpointevaluations will use the FAS as the prima All efficacy ry analysis set. For all planned inferential analyses, alternative models/methods may be considered if convergence cannot be achieved.
View Source
Efficacy Analyses. Efficacy will be assessed over 52 weeks, by the mean change from baseline in BCVA and central foveal thickness to the values at week 24 and week 52. Descriptive statistics for the change in BCVA, central foveal thickness, macular perimetry, and NEI VFQ-25 from baseline to week 24 and 52 will be presented, along with the corresponding 95% confidence intervals. In addition to analysis of the total sample population, efficacy analysis will also be performed for stratified groups (visual acuity, lesion characteristics).
View Source

Related to Efficacy Analyses

  • Technology Research Analyst Job# 1810 General Characteristics

  • Studies The clinical, pre-clinical and other studies and tests conducted by or on behalf of or sponsored by the Company or its subsidiaries that are described or referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus were and, if still pending, are being conducted in accordance in all material respects with all statutes, laws, rules and regulations, as applicable (including, without limitation, those administered by the FDA or by any foreign, federal, state or local governmental or regulatory authority performing functions similar to those performed by the FDA). The descriptions of the results of such studies and tests that are described or referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus are accurate and complete in all material respects and fairly present the published data derived from such studies and tests, and each of the Company and its subsidiaries has no knowledge of other studies or tests the results of which are materially inconsistent with or otherwise call into question the results described or referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus. Except as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, neither the Company nor its subsidiaries has received any notices or other correspondence from the FDA or any other foreign, federal, state or local governmental or regulatory authority performing functions similar to those performed by the FDA with respect to any ongoing clinical or pre-clinical studies or tests requiring the termination or suspension of such studies or tests. For the avoidance of doubt, the Company makes no representation or warranty that the results of any studies, tests or preclinical or clinical trials conducted by or on behalf of the Company will be sufficient to obtain governmental approval from the FDA or any foreign, state or local governmental body exercising comparable authority.

  • Quantitative Analysis Quantitative analysts develop and apply financial models designed to enable equity portfolio managers and fundamental analysts to screen potential and current investments, assess relative risk and enhance performance relative to benchmarks and peers. To the extent that such services are to be provided with respect to any Account which is a registered investment company, Categories 3, 4 and 5 above shall be treated as “investment advisory services” for purposes of Section 5(b) of the Agreement.”

  • Risk Analysis The Custodian will provide the Fund with a Risk Analysis with respect to Securities Depositories operating in the countries listed in Appendix B. If the Custodian is unable to provide a Risk Analysis with respect to a particular Securities Depository, it will notify the Fund. If a new Securities Depository commences operation in one of the Appendix B countries, the Custodian will provide the Fund with a Risk Analysis in a reasonably practicable time after such Securities Depository becomes operational. If a new country is added to Appendix B, the Custodian will provide the Fund with a Risk Analysis with respect to each Securities Depository in that country within a reasonably practicable time after the addition of the country to Appendix B.

  • Protocols Each party hereby agrees that the inclusion of additional protocols may be required to make this Agreement specific. All such protocols shall be negotiated, determined and agreed upon by both parties hereto.